S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial

Agile Therapeutics (AGRX) News Today

→ The #1 Opportunity of the decade? (From Behind the Markets) (Ad)
Free AGRX Stock Alerts
$0.38
+0.01 (+2.70%)
(As of 04:27 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability
SourceHeadline
MarketBeat logoAgile Therapeutics (NASDAQ:AGRX) versus Organogenesis (NASDAQ:ORGO) Head to Head Comparison
americanbankingnews.com - April 13 at 1:44 AM
MarketBeat logoAgile Therapeutics (NASDAQ:AGRX) Now Covered by Analysts at StockNews.com
americanbankingnews.com - April 12 at 2:18 AM
finance.yahoo.com logoAgile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript
finance.yahoo.com - April 1 at 10:19 PM
seekingalpha.com logoAgile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 30 at 2:20 PM
investorplace.com logoAGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023
investorplace.com - March 29 at 9:02 PM
finance.yahoo.com logoQ4 2023 Agile Therapeutics Inc Earnings Call
finance.yahoo.com - March 29 at 3:16 AM
markets.businessinsider.com logoHere's what to expect from Agile Therapeutics's earnings report
markets.businessinsider.com - March 28 at 5:14 PM
finanznachrichten.de logoAgile Therapeutics, Inc.: Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - March 28 at 11:12 AM
globenewswire.com logoAgile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
globenewswire.com - March 28 at 8:05 AM
msn.com logoWhy Agile Therapeutics (AGRX) Stock Is Down 60%
msn.com - March 26 at 2:07 PM
finanznachrichten.de logoAgile Therapeutics, Inc.: Agile Therapeutics Announces Delisting from Nasdaq
finanznachrichten.de - March 26 at 9:06 AM
globenewswire.com logoAgile Therapeutics Announces Delisting from Nasdaq
globenewswire.com - March 25 at 4:30 PM
benzinga.com logoLatest News for Agile Therapeutics Stock (NASDAQ:AGRX)
benzinga.com - March 23 at 8:00 AM
markets.businessinsider.com logoAgile Therapeutics is about to announce its earnings — here's what to expect
markets.businessinsider.com - March 21 at 10:51 AM
benzinga.com logoAgile Therapeutics's Earnings: A Preview
benzinga.com - March 21 at 10:51 AM
globenewswire.com logoCorrection - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
globenewswire.com - March 21 at 6:35 AM
globenewswire.com logoAgile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
globenewswire.com - March 20 at 8:15 AM
msn.com logoAgile Therapeutics stock soars on complete debt payoff
msn.com - March 13 at 12:55 PM
globenewswire.com logoAgile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
globenewswire.com - March 13 at 7:31 AM
investing.com logoAgile Therapeutics reduces warrant exercise price
investing.com - February 24 at 11:50 PM
benzinga.com logoAgile Therapeutics Stock (NASDAQ:AGRX), Short Interest Report
benzinga.com - February 22 at 7:35 PM
benzinga.com logoWhat's Going On With Women Health Focused Agile Therapeutics Stock Today?
benzinga.com - February 22 at 2:32 PM
finance.yahoo.com logoAgile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
finance.yahoo.com - February 22 at 9:32 AM
investorplace.com logoWhy Is Agile Therapeutics (AGRX) Stock Up 87% Today?
investorplace.com - February 22 at 9:11 AM
globenewswire.com logoAgile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
globenewswire.com - February 22 at 9:01 AM
investorplace.com logoWhy Is Agile Therapeutics (AGRX) Stock Up 87% Today?
investorplace.com - February 22 at 7:57 AM
msn.com logoAgile Therapeutics reports higher prelim FY revenue than last year
msn.com - February 15 at 7:39 PM
finance.yahoo.com logoAgile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
finance.yahoo.com - February 15 at 7:39 PM
globenewswire.com logoAgile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance Update
globenewswire.com - February 15 at 4:30 PM
markets.businessinsider.com logoBuy Rating for Agile Therapeutics: Regulatory Tailwinds and Strong Sales Growth Forecast
markets.businessinsider.com - January 25 at 5:27 AM
finance.yahoo.com logoThe Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
finance.yahoo.com - January 23 at 11:06 AM
finance.yahoo.com logoAgile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
finance.yahoo.com - December 12 at 9:19 AM
msn.com logoAgile Therapeutics reports Q3 results
msn.com - November 23 at 8:51 AM
benzinga.com logoAgile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
benzinga.com - November 21 at 9:11 AM
markets.businessinsider.com logoAgile Therapeutics: A Promising Investment with Positive Cash Flow Forecasts and Anticipated Growth in Twirla Sales
markets.businessinsider.com - November 11 at 7:49 AM
finance.yahoo.com logoAgile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 10 at 10:58 AM
finance.yahoo.com logoAgile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 8:14 AM
msn.com logoAgile Therapeutics Q3 2023 Earnings Preview
msn.com - November 8 at 4:56 PM
finance.yahoo.com logoAgile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
finance.yahoo.com - October 26 at 8:52 AM
finanznachrichten.de logoAgile Therapeutics, Inc.: Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
finanznachrichten.de - October 5 at 9:58 AM
finance.yahoo.com logoAgile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - October 4 at 6:38 PM
finanznachrichten.de logoAgile Therapeutics, Inc.: Agile Therapeutics Upgraded To "Buy" Rating By Analysts At Maxim Group
finanznachrichten.de - September 30 at 11:02 PM
finance.yahoo.com logoAgile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
finance.yahoo.com - September 28 at 12:55 PM
benzinga.com logoAgile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group
benzinga.com - September 27 at 8:42 AM
finance.yahoo.com logoAgile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - September 5 at 5:38 PM
msn.com logoAgile ($AGRX) Says It's On Track To Hit $25-$30M Net Annual Revenue After A Strong Performance In Q2
msn.com - August 17 at 5:17 PM
finance.yahoo.com logoAgile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript
finance.yahoo.com - August 11 at 6:10 PM
finanznachrichten.de logoAgile Therapeutics, Inc.: Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - August 9 at 9:07 PM
finance.yahoo.com logoAgile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 11:06 AM
finance.yahoo.com logoAgile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
finance.yahoo.com - July 26 at 5:43 PM
Get Agile Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

AGRX Media Mentions By Week

AGRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AGRX
News Sentiment
▼
0.00

0.52
▲
Average
Medical
News Sentiment

AGRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AGRX Articles
This Week
▼
1

1
▲
AGRX Articles
Average Week

Get Agile Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:AGRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative